A pilot assessment of oxidative stress byproducts and antioxidant activities among indian patients with various stages of hypertension

Clinical and Experimental Hypertension

Volumn 33, Issue 7, 2011, Pages 437-443

  Saraswathi, Raman ^a   Sankar, Devarajan ^b   Ali, Amanat ^c   Uehara, Yoshinari ^d   Abe, Satomi ^d   Sambandam, Ganapathy ^e   Rao, M Ramakrishna ^f  

^a Department of Biochemistry   (India)

^b Fukuoka University Chikushi Hospital   (Japan)

^c SULTAN QABOOS UNIVERSITY   (Oman)

^d FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^e Department Maniarasan Memorial Poly Clinic ^*  (India)

^f ANNAMALAI UNIVERSITY   (India)

Author keywords

Antioxidants; Lipid peroxidation; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CATALASE; COPPER; DIURETIC AGENT; ELECTROLYTE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LIPID; MAGNESIUM; MINERAL; POTASSIUM ION; SODIUM ION; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ZINC;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE COURSE; ELECTROLYTE BLOOD LEVEL; ENZYME ACTIVITY; ERYTHROCYTE; ETHNIC GROUP; HUMAN; HYPERTENSION; INDIA; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PILOT STUDY; PLASMA;

ADULT; ANTIOXIDANTS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; HUMANS; HYPERTENSION; INDIA; LIPID PEROXIDATION; LIPIDS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PILOT PROJECTS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 80053630551     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2010.549259     Document Type: Article

References (45)

1. Wang W, Lee ET, Fabsitz RR,Devereaux R, Best L, Welty TK, Howard BV. Longitudinal study of hypertension risk factors and their relation to cardiovascular disease. The Strong Heart Study. Hypertension 2006;47: 403-409.
2. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-381.
3. Xu JZ, Zhang Y, Wu SN, Niu WQ, Zhu DL, Gao PJ. Impaired endothelial function in hypertensive patients with target organ damage. J Hum Hypertens 2009;23:751-757.
4. Pollock DM. Endothelin, angiotensin, and oxidative stress in hypertension. Hypertension 2005;45:477.
5. Chilsom GM, Steimberg D. The oxidative modification hypothesis of atherogenesis: an overview. Fre Rad Biol Med 2000;28:1815-1826.
6. Hermann M, Flammer A, Lüscher TF. Nitric oxide in hypertension. J Clin Hypertens (Greenwich). 2006;8(12 suppl 4): 17-29.
7. Redon J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Saez GT. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003;41:1096-1101.
8. Rhian M. Touyz. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension. What is the clinical significance? Hypertension 2004;44:248-252.
9. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342: 836-843.
10. Kuller LH, Tracy RP, Shaten J, Meilahn EN, for the MRFIT Research Group. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144: 537-547.
11. Di Napoli M, Papa F, for the Villa Pini Stroke Data Bank Investigators. Inflammation, hemostatic markers and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002;33:1763-1771.
12. Di Napoli M, Papa F. C-reactive protein and blood pressure in the acute phase after an ischemic stroke. Stroke 2003;34:839.
13. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo, Jr JL, Jones DW, Materson BJ, Oparil S, Wright, Jr JT, Roccella EJ, the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42: 1206-1252.
14. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 20:1075.
15. Warnick GR, Nguyen T, Alberts AA. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. Clin Chem 1985;31:217.
16. Rifai N, Bachorik PS, Alberts JJ. Lipids, lipoproteins and apolipoproteins. In: Burtis CA, Ashwood ER, eds. Tietz Textbook of Clinical Chemistry, 3rd ed. Philadelphia: WB Saunders Company; 1999;809-861.
17. Friedewald WT, Lewy RI, Fredrickson DS. Estimation of concentration of the low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
18. Nichans Jr WG, Samuelson B. Formation of malondialdehyde from phospholipids arachidonate during microsomal lipid peroxidation. Eur J Biochem 1968;6:126-130.
19. Gowenlock A. Electrolyte and acid base disturbances. In: Varley's Practical Clinical Biochemistry, 6th ed. Boca Raton, FL: CRC Press; 1988; 550-600.
20. Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of superoxide dismutase. Ind J Biochem Biophys 1984;21:130-132.
21. Rotruck JT, Pope AL, Ganther HE, Swanson AB. Selenium: biochemical roles as component of glutathione peroxidase. Science 1973;179:588-590.
22. Sinha KA. Colorimetric assay of catalase. Anal Biochem 1972;47:389-394.
23. Roe JH, Kuether CA. Detection of ascorbic acid in whole blood and urine through the 2,4-dinitrophyenyl hydrazine of dehydroascorbic acid. J Biol Chem 1943;147:399-407.
24. Baker H, Frank O, De Angelis B, Feingold S. Plasma tocopherol in man at various times after ingesting free or acetylated tocopherol. Nutr Res Int 1980;21:399-407.
25. Bradely DW, Hornebeck CLC. Clinical evaluation of an improved TFA micro method for plasma and serum vitamin A. Biochem Med 1973;7:78-86.
26. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-77.
27. Snedecor GW, Cochran WG. Statistical Methods. 8th ed. Ames, IA: The Iowa State University Press, 1989.
28. Packer L. Cell regulation by thiol antioxidants: from glutathione to lipoate to anethole dithiolethione. In: Packer L. Traber MG. Xin W, eds. Proceedings of the International Symposium on Natural Antioxidants Molecular Mechanisms and Health Effects. Champaign, IL: AOCS Press; 1995; 223-235.
29. Griffiths NR, Moller L, Bartosz G, Bast A, Bertoni-Freddari C, Collins A, Cooke M, Coolen S, Haenen G, Hoberg AM, Loft S, Lunec J, Olinski R, Parry J, Pompella A, Poulsen H, Verhagen H, Astley SB. Biomarkers. Mol Aspects Med 2002;23: 101-208.
30. Nagyová A,Mongiellová V, Krivosíková Z, et al. Vitamin E supplementation in patients with ischemic heartdisease: effect on in vitro LDL oxidation. Biologia, Bratislava 2001;56:655-660.
31. Juurlink, BHJ. Management of oxidative stress in the CNS: the many roles of glutathione. Neurotox Res 1999;1:119-140.
32. Steinberg D, Parthasarthy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
33. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003;108:2993-2999.
34. Savoia C, Schiffrin EL. Inflammation in hypertension. Current Opin Nephrol Hypertens 2006;2:152-158.
35. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (London) 2007;112:375-384.
36. Verma S, Yeh ET. C-reactive protein and atherothrombosis- beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol 2003;285:R1253-R1256.
37. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003;107:1783-1790.
38. Dahl LK: Salt and hypertension. Am J Clin Nutr 1972;25: 231-244.
39. Mancilha-Carvalho JJ, Oliveira R, Esposito RJ: Blood pressure and electrolyte excretion in the Yanomamo Indians, an isolated population. J Hum Hypertens 1989;3:309-314.
40. Klevay LM. Coronary heart disease: the zinc/copper hypothesis. Am J Clin Nutr 1975; 28:764-774.
41. Stadler N, Lindner RA, Davies MJ. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 2004;24(5):949-954.
42. Richard B. Elevated level of serum copper and magnesium in normotensives and untreated and treated hypertensives. Nutr Rep Int 1983;27:1013-1020.
43. Klevay LM. Hypertension in rats deficient in copper. Fed Proc 1986;45:235.
44. Laurant P, Touyz RM. Physiological and pathophysiological role of magnesium in the cardiovascular system: implications in hypertension. J Hypertens 2000;18:1177-1191.
45. 2+ in rat aortic smooth muscle cells. Cardiovasc Res 2005;65: 387-396.